Last Updated: September 24, 2026

Details for Patent: 11,844,858

Name: Drug Patent Intelligence for US Patent 11844858
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,844,858 protect, and when does it expire?

Patent 11,844,858 protects RYZUMVI and is included in one NDA.

This patent has ten patent family members in eight countries.

Summary for Patent: 11,844,858

Title:	Aqueous ophthalmic solutions of phentolamine and medical uses thereof
Abstract:	The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
Inventor(s):	Alan R. Meyer
Assignee:	Opus Genetics Inc
Application Number:	US17/401,604
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,844,858
Patent Claim Types: see list of patent claims	Formulation; Compound;

Drugs Protected by US Patent 11,844,858

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,844,858

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014212274	⤷ Start Trial
Australia	2018200566	⤷ Start Trial
Canada	2899339	⤷ Start Trial
Denmark	2950648	⤷ Start Trial
European Patent Office	2950648	⤷ Start Trial
Spain	2762153	⤷ Start Trial
Japan	2016506966	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.